Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Arrowhead Pharmaceuticals Inc ARWR

Healthcare Biotechnology

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform... see more

Add To Watchlist

Recent & Breaking News (NDAQ:ARWR)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017

Business Wire December 21, 2016

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit – ARWR

GlobeNewswire December 20, 2016

Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Arrowhead Pharmaceuticals, Inc. Investors and Encourages Investors to Contact the Firm

Business Wire December 19, 2016

ARWR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Shareholders of Commencement of a Class Action Involving Arrowhead Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of January 17, 2017

Business Wire December 16, 2016

Arrowhead Reports Fiscal 2016 Year End Results

Business Wire December 14, 2016

ARWR NOTICE: Rosen Law Firm Reminds Arrowhead Pharmaceuticals, Inc. Investors of Important Deadline in Class Action - ARWR

Business Wire December 8, 2016

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results

Business Wire December 7, 2016

EXPANDED CLASS PERIOD: Levi & Korsinsky, LLP Reminds Shareholders of Arrowhead Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2017 – ARWR

GlobeNewswire December 7, 2016

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Arrowhead Pharmaceuticals, Inc. (ARWR) & Lead Plaintiff Deadline: January 16, 2017

GlobeNewswire December 5, 2016

INVESTOR ALERT: Stull, Stull & Brody Filed a Securities Class Action Lawsuit on Behalf of Purchasers of Arrowhead Pharmaceuticals, Inc. Common Stock and Encourages Shareholders with Losses to Contact the Firm

GlobeNewswire December 2, 2016

The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Arrowhead Pharmaceuticals, Inc. Investors and Encourages Investors to Contact the Firm

Business Wire November 30, 2016

Mid-Morning Market Update: Markets Mostly Higher; GoPro To Reduce 15% Of Workforce

Benzinga.com November 30, 2016

Alnylam Is Now The Leader In The Clinical HBV RNAi Therapy Space

Benzinga.com November 30, 2016

The Market In 5 Minutes: OPEC, Earnings And Trump's Cabinet

Benzinga.com November 30, 2016

25 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com November 30, 2016

Arrowhead Pharmaceuticals Focuses Resources on Subcutaneous and Extra-Hepatic RNAi Therapeutics

Business Wire November 29, 2016

Research Reports Initiation on Biotech Stocks -- ImmunoGen, Puma Biotech, Arrowhead Pharma, and Intra-Cellular Therapies

PR Newswire November 28, 2016

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

Business Wire November 25, 2016

Robbins Arroyo LLP: Arrowhead Pharmaceuticals, Inc. (ARWR) Misled Shareholders According to a Recently Filed Class Action

Business Wire November 23, 2016

ARWR LOSS ALERT: Rosen Law Firm Reminds Arrowhead Pharmaceuticals, Inc. Investors of Important Deadline in Class Action- ARWR

PR Newswire November 22, 2016